---
title: "VK2735 in Chronic weight management: Generic, brand name and therapeutic class of product"
description: "Formulary evidence on VK2735 in Chronic weight management: Generic, brand name and therapeutic class of product. Topics: Manufacturer: Viking Therapeutics, Name: development code VK2735, Brand name: one brand name expected for both formulations, Therapeutic class: dual GLP-1 and GIP receptor agonist, and 1 further topic. 5 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description/generic-brand-name-and-therapeutic-class-of-product"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: Generic, brand name and therapeutic class of product

<a id="heading-2.1.2.1"></a>

## 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

### Manufacturer: Viking Therapeutics

> “Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter and nine months ended September 30, 2026”
> “VK2735 is a wholly owned long-acting dual agonist of the glucagon like peptide-1, or GLP-1 receptor, and the glucose dependent insulinotropic polypeptide, or GIP receptor, in development for the potential treatment of obesity and other metabolic disorders.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

> “Viking retains ownership of all global rights to VK2735 under the agreement and expects to maintain standard pharmaceutical product margins.”

Source: [Viking Therapeutics CordenPharma agreement release (2025)](https://ir.vikingtherapeutics.com/2025-03-11-Viking-Therapeutics-Signs-Broad-Manufacturing-Agreement-With-CordenPharma-to-Support-Commercialization-of-VK2735)

> “Viking selected VK2735 from a series of internally developed dual GLP-1/GIP receptor agonists”

Source: [Viking Therapeutics VK2735 pipeline page](https://vikingtherapeutics.com/pipeline/vk2735/)

<a id="topic-2.1.2.1-2"></a>

### Name: development code VK2735

> “today announced the initiation of a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.”

Source: [Viking Therapeutics phase 1 initiation release (2022)](https://ir.vikingtherapeutics.com/2022-01-10-Viking-Therapeutics-Announces-Initiation-of-Phase-1-Clinical-Trial-of-VK2735,-Companys-Lead-Dual-GLP-1-GIP-Receptor-Agonist)

<a id="topic-2.1.2.1-3"></a>

### Nonproprietary name

No evidence found.

<a id="topic-2.1.2.1-4"></a>

### Brand name: one brand name expected for both formulations

> “We're going to have the second injectable dual agonist. We're going to have the first GLP-1/GIP dual agonist oral. It's the same molecule, so you'd expect it to be the same brand name.”

Source: [Viking Therapeutics Morgan Stanley conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/744429-morgan-stanley-24th-annual-global-healthcare-conference/)

<a id="topic-2.1.2.1-5"></a>

### Therapeutic class: dual GLP-1 and GIP receptor agonist

> “VK2735 is a dual agonist of the GLP-1 and GIP receptors that we are developing for the potential treatment for various metabolic disorders.”

Source: [Viking Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1607678/000119312526046876/vktx-20251231.htm)

> “This study aimed to determine doses of VK2735, a novel glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide (GLP‐1/GIP) receptor dual agonist, that are effective for weight loss over 13 weeks of treatment.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-2.1.2.1-6"></a>

### Chemical class: peptide with a half-life-extending side chain

> “The VK2735 peptide incorporates the activities of both incretins and contains a side chain that imparts an extended half‐life when administered as a subcutaneous injection.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-2.1.2.1-7"></a>

### Chemical structure, molecular formula, and molecular weight

No evidence found.

Additional sources: [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500); [ClinicalTrials.gov NCT07868835](https://clinicaltrials.gov/study/NCT07868835)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
